{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:19:38Z","timestamp":1790493578143,"version":"4.1.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T00:00:00Z","timestamp":1523318400000},"content-version":"vor","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-DT1113"],"award-info":[{"award-number":["SU2C-AACR-DT1113"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancercell.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ccell.2017.03.002","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T16:00:39Z","timestamp":1490889639000},"page":"476-485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":134,"title":["Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers"],"prefix":"10.1016","volume":"31","author":[{"given":"Robbie G.","family":"Majzner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Heitzeneder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2017.03.002_bib1","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T\u00a0cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2017.03.002_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/mt.2013.262","article-title":"Kinetics of tumor destruction by chimeric antigen receptor-modified T\u00a0cells","volume":"22","author":"Anurathapan","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ccell.2017.03.002_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2017.03.002_bib6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.03.002_bib7","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib8","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","article-title":"Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency","volume":"34","author":"Bouffet","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib10","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T\u00a0cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.03.002_bib11","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib12","doi-asserted-by":"crossref","unstructured":"Burgess, M., Crowley, J., Reinke, D., Riedel, R., George, S., Movva, S., Van Tine, B.A., Davis, L.E., Schuetze, S., Hu, J., et\u00a0al. (2015). SARC 028: a phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. Paper presented at: American Society of Clinical Oncology.","DOI":"10.1200\/jco.2015.33.15_suppl.tps10578"},{"key":"10.1016\/j.ccell.2017.03.002_bib13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fonc.2015.00083","article-title":"Targeting the innate immune system as immunotherapy for acute myeloid leukemia","volume":"5","author":"Curran","year":"2015","journal-title":"Front Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib15","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T\u00a0cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2017.03.002_bib17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/359162a0","article-title":"Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours","volume":"359","author":"Delattre","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2017.03.002_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MPH.0000000000000000","volume":"36","author":"Duffner","year":"2014","journal-title":"J.\u00a0Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib19","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2011.37.4546","article-title":"Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group","volume":"30","author":"Ebb","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/ng.3333","article-title":"Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations","volume":"47","author":"Eleveld","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2017.03.002_bib21","doi-asserted-by":"crossref","first-page":"11111","DOI":"10.1038\/ncomms11111","article-title":"Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy","volume":"7","author":"Findlay","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2017.03.002_bib22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood.V18.4.431.431","article-title":"Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate","volume":"18","author":"Frei","year":"1961","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.03.002_bib23","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1464-410X.2010.09224.x","article-title":"Risk of bladder tumours after childhood cancer: the British Childhood Cancer Survivor Study","volume":"106","author":"Frobisher","year":"2010","journal-title":"BJU Int."},{"key":"10.1016\/j.ccell.2017.03.002_bib24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/ng1193-230","article-title":"Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma","volume":"5","author":"Galili","year":"1993","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2017.03.002_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/COC.0b013e318210f533","article-title":"Second tumors in pediatric patients treated with radiotherapy to the central nervous system","volume":"35","author":"Galloway","year":"2012","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib26","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.03.002_bib27","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib28","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T\u00a0cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.03.002_bib29","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00262-016-1859-9","article-title":"Modulation of innate immunity in the tumor microenvironment","volume":"65","author":"Gonzalez-Gugel","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ccell.2017.03.002_bib30","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3703.3703","article-title":"Initial results from a phase 2 study of blinatumomab in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"124","author":"Gore","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.03.002_bib31","first-page":"3196","article-title":"Detection of N-myc oncogene expression in human neuroblastoma by in\u00a0situ hybridization and blot analysis: relationship to clinical outcome","volume":"46","author":"Grady-Leopardi","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2017.03.002_bib32","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.03.002_bib33","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.03.002_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-16-0223","article-title":"Metastatic melanoma patient had complete response with clonal expansion after whole brain radiation and PD-1 blockade","volume":"5","author":"Haymaker","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2017.03.002_bib35","unstructured":"Heczey A., L.C.U., Savoldo B., Dakhova O., Grilley B.J., Gee A., Dotti GP, Heslop H.E., Rooney C.M., Brenner M.K. (2016). Autologous T\u00a0cells expressing a GD2 specific chimeric antigen receptor with CD28 and OX40 costimulatory endodomains for children with neuroblastoma. Paper presented at: Advances in Neuroblastoma Research Congress."},{"key":"10.1016\/j.ccell.2017.03.002_bib36","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T\u00a0cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2017.03.002_bib37","doi-asserted-by":"crossref","first-page":"e87415","DOI":"10.1172\/jci.insight.87415","article-title":"Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer","volume":"1","author":"Herter-Sprie","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ccell.2017.03.002_bib38","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1593\/tlo.12280","article-title":"A systemic complete response of metastatic melanoma to local radiation and immunotherapy","volume":"5","author":"Hiniker","year":"2012","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib39","article-title":"Potent anti-leukemia activities of chimeric antigen receptor modified T\u00a0cells against CD19 in Chinese patients with relapsed\/refractory acute lymphocytic leukemia","author":"Hu","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2017.03.002_bib40","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2017.03.002_bib41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/PDM.0b013e31821c30bc","article-title":"Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults","volume":"20","author":"Jha","year":"2011","journal-title":"Diagn. Mol. Pathol."},{"key":"10.1016\/j.ccell.2017.03.002_bib42","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T\u00a0cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.03.002_bib43","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T\u00a0cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.03.002_bib44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/15384047.2016.1264543","article-title":"Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone","volume":"18","author":"Koller","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ccell.2017.03.002_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2016.11.001","article-title":"Peptide vaccines in cancer-old concept revisited","volume":"45","author":"Kumai","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ccell.2017.03.002_bib46","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2015.65.5381","article-title":"Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through children's cancer group, pediatric oncology group, and children's oncology group: learning from the past to move forward","volume":"34","author":"Lagmay","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib47","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/jnci\/djp498","article-title":"Educational attainment among adult survivors of childhood cancer in Great Britain: a population-based cohort study","volume":"102","author":"Lancashire","year":"2010","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ccell.2017.03.002_bib48","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib49","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.03.002_bib50","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2017.03.002_bib51","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.4049\/jimmunol.1490027","article-title":"Translational medicine in action: anti-CD20 therapy in lymphoma","volume":"193","author":"Lim","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2017.03.002_bib52","doi-asserted-by":"crossref","first-page":"e1214788","DOI":"10.1080\/2162402X.2016.1214788","article-title":"Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma","volume":"5","author":"Liniker","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ccell.2017.03.002_bib53","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T\u00a0cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib54","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T\u00a0cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib55","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","article-title":"Reduction of MDSCs with All-trans retinoic acid improves CAR therapy efficacy for sarcomas","volume":"4","author":"Long","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2017.03.002_bib56","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T\u00a0cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"#cr-split#-10.1016\/j.ccell.2017.03.002_bib57.1","doi-asserted-by":"crossref","unstructured":"Majzner, R.G., Walker, A.J., Murgai, M., Zhang, L., Long, A.H., Wanhainen, K.M., Orentas, R.J., Mackall, C.L. (2016). Chimeric antigen receptor T-cell therapy against anaplastic lymphoma kinase (ALK) is limited by target antigen density and CAR surface expression. Proceedings: AACR 107th Annual Meeting 2016","DOI":"10.1158\/1538-7445.AM2016-2648"},{"key":"#cr-split#-10.1016\/j.ccell.2017.03.002_bib57.2","unstructured":"April 16-20, 2016. 10.1158\/1538-7445.AM2016-2648."},{"key":"10.1016\/j.ccell.2017.03.002_bib58","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib59","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T\u00a0cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ccell.2017.03.002_bib60","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-15-2550","article-title":"Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas","volume":"22","author":"Merchant","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2017.03.002_bib61","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","article-title":"Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors","volume":"22","author":"Merchant","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2017.03.002_bib62","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2016.06.017","article-title":"Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody","volume":"66","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ccell.2017.03.002_bib63","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.coi.2013.01.004","article-title":"The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy","volume":"25","author":"Moran","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ccell.2017.03.002_bib64","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T\u00a0cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ccell.2017.03.002_bib65","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib66","article-title":"Genomic evolution after chemoradiotherapy in anal squamous cell carcinoma","author":"Mouw","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2017.03.002_bib67","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/nm.4200","article-title":"Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses","volume":"22","author":"Moynihan","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib68","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2011.40.3287","volume":"30","author":"Oberlin","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib69","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2010.34.0000","article-title":"R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study","volume":"29","author":"Pappo","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib70","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1126\/science.1198056","article-title":"The genetic landscape of the childhood cancer medulloblastoma","volume":"331","author":"Parsons","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ccell.2017.03.002_bib71","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T\u00a0cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib72","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib73","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib74","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2017.03.002_bib75","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T\u00a0cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib76","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1182\/blood.V126.23.4427.4427","article-title":"Preclinical development of bispecific chimeric antigen receptor targeting both CD19 and CD22","volume":"126","author":"Qin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.03.002_bib77","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","article-title":"Eradication of B-ALL using chimeric antigen receptor-expressing T\u00a0cells targeting the TSLPR oncoprotein","volume":"126","author":"Qin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.03.002_bib78","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib79","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib80","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jama.2010.923","article-title":"Long-term cause-specific mortality among survivors of childhood cancer","volume":"304","author":"Reulen","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ccell.2017.03.002_bib81","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ccell.2017.03.002_bib82","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ccell.2017.03.002_bib83","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib84","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2017.03.002_bib85","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib86","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib87","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2017.03.002_bib88","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2017.03.002_bib89","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T\u00a0cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2017.03.002_bib90","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3324\/haematol.2013.100073","article-title":"Pediatric posttransplant relapsed\/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab","volume":"99","author":"Schlegel","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ccell.2017.03.002_bib91","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3349","article-title":"Mutational dynamics between primary and relapse neuroblastomas","volume":"47","author":"Schramm","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2017.03.002_bib92","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ccell.2017.03.002_bib93","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/305245a0","article-title":"Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour","volume":"305","author":"Schwab","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2017.03.002_bib94","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood.V128.22.650.650","article-title":"Minimal residual disease negative complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL)","volume":"128","author":"Shah","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2017.03.002_bib95","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mpo.10248","article-title":"Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma","volume":"40","author":"Shankar","year":"2003","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib96","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/ng.3202","article-title":"Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers","volume":"47","author":"Shlien","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2017.03.002_bib97","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib98","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1200\/JCO.2009.27.0421","article-title":"Outcomes for children and adolescents with cancer: challenges for the twenty-first century","volume":"28","author":"Smith","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib99","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib100","doi-asserted-by":"crossref","first-page":"E2646","DOI":"10.1073\/pnas.1604268113","article-title":"Durable antitumor responses to CD47 blockade require adaptive immune stimulation","volume":"113","author":"Sockolosky","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2017.03.002_bib101","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2017.03.002_bib102","doi-asserted-by":"crossref","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","article-title":"Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma","volume":"113","author":"Spranger","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2017.03.002_bib103","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijrobp.2012.03.017","article-title":"The abscopal effect associated with a systemic anti-melanoma immune response","volume":"85","author":"Stamell","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ccell.2017.03.002_bib104","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fonc.2016.00233","article-title":"Combination approaches with immune-checkpoint blockade in cancer therapy","volume":"6","author":"Swart","year":"2016","journal-title":"Front Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib105","doi-asserted-by":"crossref","unstructured":"Taraseviciute, A., Kean, L., and Jensen, M. (2016). Creation of the first non-human primate model that faithfully recapitulates chimeric antigen receptor (CAR) T\u00a0cell-mediated cytokine release syndrome (CRS) and neurologic toxicity following B cell-directed CAR-T cell therapy. Paper presented at: Blood.","DOI":"10.1182\/blood.V128.22.651.651"},{"key":"10.1016\/j.ccell.2017.03.002_bib106","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2009.27.0090","article-title":"Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study","volume":"28","author":"Taylor","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib107","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2017.03.002_bib108","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2017.03.002_bib109","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib111","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/CJI.0b013e3180de5d90","article-title":"Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction","volume":"30","author":"Turatti","year":"2007","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ccell.2017.03.002_bib112","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2017.03.002_bib113","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/cpt.392","article-title":"CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies","volume":"100","author":"Turtle","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ccell.2017.03.002_bib114","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/28212","article-title":"Truncating mutations of hSNF5\/INI1 in aggressive paediatric cancer","volume":"394","author":"Versteege","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2017.03.002_bib115","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2017.03.002_bib116","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/pbc.24605","article-title":"Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group","volume":"61","author":"Weigel","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ccell.2017.03.002_bib117","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.gt.3301051","article-title":"Functional balance between T\u00a0cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production","volume":"7","author":"Weijtens","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.ccell.2017.03.002_bib118","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ng.1102","article-title":"Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas","volume":"44","author":"Wu","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2017.03.002_bib119","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/pbc.24237","article-title":"Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets","volume":"59","author":"Yankelevich","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ccell.2017.03.002_bib120","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610817300648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610817300648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T09:30:46Z","timestamp":1657704646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610817300648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":121,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1535610817300648"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2017.03.002","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2017.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}